Why the study?
The study was conducted to introduce ECG digitalisation and the Smart ECG program to evaluate the effectiveness of ranolazine and optimize the treatment of ST segment elevation syndrome.
Does the addition of ranolazine to standard therapy improve ECG markers of electrical instability and quality of life in patients with STEMI?
Does the addition of ranolazine to standard therapy improve ECG markers of electrical instability and quality of life in patients with STEMI?
Answers are grounded in this paper and cite their sources.
Adding ranolazine to standard therapy in STEMI patients may improve early quality of life and stabilize ECG markers of electrical myocardial instability.
This paper presents the possibility and expediency of using information systems in diagnostics – ECG digitalization and «Smart-ECG» implementation with analysis of ranolasine efficiency, optimization of treatment of ST segment elevation syndrome. Purpose – to introduce ECG digitalisation and the program «Smart ECG» to evaluate the effectiveness of ranolasine and to optimize the treatment of ST segment elevation syndrome. Material and methods. We examined 40 patients with Q-MI (STEMI), admitted to regional clinical cardiology center in Chernivtsi, were instituted basic therapy according to the modern recommendations which contained interventional treatment with restoration of patency of a heart attack-conditioned coronary artery, double antiplatelet therapy, statins, β- adrenergic blocker, angiotensin-converting enzyme inhibitors, aldosterone antagonists with edition of ranolasine (group I, 30 patients diagnosed STEMI). Control - group II, 10 patients STEMI, who received basic therapy without addition of ranolasine. Results. Own results allow us to determine the positive effect of ranolazine on stabilization of the studied indicators of ECG digitalization according to the heart rate variability (SDNN) and QT variability (dQT), phenomena of the phase of repolarization («angle QRS-T» and “ST slope”), the first derivative of ECG ratio of maximum velocity of the differentiated deflection T and the definition of quality of life according to the EQ-5D-3L questionnaire, which partially presents the world approach. Conclusion. Analog scale EQ–VAS indicates a positive effect of Ranolazine on the quality of life of patients diagnosed with STEMI. Ranolasine (STEMI diagnosed patients) has positive influence on the markers of electrical myocardial instability and its ischemia - as evidenced: decreasing of the heart rate, probability of cases of SDNN decrease, depression of QT and maybe increase of ratio of maximum velocity for differentiated deflection T.
No takes yet. Share an insight, caveat, or question.
Тащук et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: